Novartis Belux’s Post

We are honored that Novartis has been ranked first in the 2024 Access to Medicine Index. This recognition is a testimony of our commitment to improving access to breakthrough medicines for people around the world, regardless of their location or socio-economic status. Our commitment to patients is at the core of our Code of Ethics, where we reinforce our responsibility to systematically integrate access strategies into how we research, develop and deliver all our new medicines globally. The Code of Ethics shapes the decisions we make, and the actions we take daily. As you can see from the assessment criteria of the Index, having strong commitments to responsible business practices and effective controls to promote ethical conduct and mitigate risks are an important part of the assessment. We are grateful that our efforts in this regard were acknowledged. We will never be perfect but we take our commitments and our approach to integrated assurance very seriously. You will find the full report here: https://lnkd.in/evdpdZwM #ethics #doingbusinessethically #integratedassurance #AccessToMedicine Brett Hudson Ann-Charlott Biedermann Mitja Kandare Simon Nowack Jela Zdolsek Barbara Badoino Monika Hala Philipp Dederichs Yasmin Gamal Pavel Petrov Shefali Kothari Ben Kaye-Smith Franziska Janorschke Gabriella Messinese Martin Potter

Progress driving change for a healthier and more inclusive future was evident at Reuters Pharma & Patient USA in Boston the other week. #REPatientUSA While “patient centered”, “patient focused”, and “patient driven” are hot terms in the life sciences industry, the processes and capabilities needed to collaborate with patient communities, generate insights, and develop solutions to drive better health outcomes, quality of life and longevity, remain immature and siloed. Truly integrating patient voices in biomedical research, clinical development, and along the entire regulatory approval and commercialization pathway is challenging for many organizations. This is because functions including patient advocacy, marketing, insights & analytics, medical affairs, patient experience, public affairs, CSR and others interpret and operationalize patient engagement differently. As an industry that conventionally regards patients as research subjects, there is a lot of work to do! 🙏 Here are some highlights from just a few of the speakers who are championing progress in their organizations and sharing learnings: Jon Zwinski of Chiesi USA, Inc. on being a B corp “we care about our social impact and we put patient impact on the same level as profitability” Negelle Morris of Novo Nordisk “The way we embed a diverse lens on culture and how people of different cultures engage with these diseases is essential” and “We measure success by the number of patients we serve” Desiree Priestley of Otsuka Pharmaceutical Companies (U.S.) “Technology alone cannot solve all the issues out there, high touch is necessary” Faye Feller of Geron Corporation “We have a debt to patients who supported us in clinical trials” and “There is a disconnect between the literature and the data we have gathered over the years which doesn’t align with the way we look at populations now” Monique G., Lupus patient advocate “Individuals who call themselves patients are equal stakeholders” Carla Tardif, Family Reach “We need to make financial health a part of the standard of care” Amy Akers Teets, Sanofi on shifting from talking about patient centricity, to “integrated patient engagement" and building an “actionable cycle of patient insights along the entire value chain” Inder Singh, Takeda Oncology on the expanded role of insights and analytics and “connecting the dots” Carmen White, Pfizer on what it takes to connect with and serve under-represented patients #patientengagement #pharma #patientvoice #actionableinsights

A great conference, followed by another Key Summary Report from the recent Patient Centricity and Engagement Conference run by Global Insight Conferences. (Best viewed in accessibility mode). In this report, I summarise key themes and points addressed by a handful of key speaker sessions. As noted, I do not take credit for any of these ideas or insights, rather I think it’s important to share knowledge so that we can collectively continue to make great steps towards innovation and progress in patient-centric medicines development. A big thank you to everyone involved in the day and a shout out to the following companies and individuals who I have referenced in this report. Shannon Altimari GSK Sujan Sivasubramaniyam CSL Behring B.V. Jefferson Courtney The Haemophilia Society Angela Rylands PhD CPyschol Kyowa Kirin International plc. 11 LONDON Victoria Harvey-Jones PhD Medscape Marta Garcia Manrique Servier Pharmaceuticals Beyza Klein Novartis #PatientEngagement #PatientAdvocacy #PatientCentricity #Bestpractices #knowledgesharing #Healthcare #Report #GIGHealth

Positive Health Outcomes Through Science Policy Policy and science intersect in ways that are crucial when it comes to public health. Effective science policy ensures that scientific advancements are achieved and translated into tangible health benefits for the public. At Maxeome, we are committed to bridging the gap between scientific research and public policy, fostering a collaborative environment where innovation thrives and health challenges are addressed systematically. Bringing science into policy guides research priorities, resource allocations, and regulatory frameworks by ensuring that the policies align with public health needs, disease prevention, medical interventions, and healthcare deliverables. Effective policies can accelerate medical innovation, safeguard public health, and sustain long-term positive health outcomes. At Maxeome, we believe in the power of collaboration and evidence-based decision-making. Our team works at the nexus of science and policy, providing evidence-based insights and strategic guidance to policymakers, researchers, and healthcare leaders. • Research: We conduct thorough research and data analysis to inform health policy decisions, ensuring they are grounded in the latest scientific evidence and geared towards improving public health outcomes. • Stakeholder Engagement: We facilitate dialogue between experts, policymakers, practitioners, and the public to build consensus and drive collective action on critical health issues. • Policy Development: We assist in developing health policies that are based on the best available data to enhance healthcare access and protect public health. • Advocacy: We advocate for science-based health policies and encourage stakeholders to consider the critical role of scientific evidence in health policy-making. At Maxeome, we're passionate about transforming biomedical research and innovation to accelerate positive health outcomes. Be a partner and learn more at www.maxeome.com #BiotechStartups #Biopharma #Biotech #Healthcare #EvidenceBased #BiomedicalResearch #MedicalResearch #Innovation #Science #PublicHealth #Research #Startup #SaudiArabia #SciencePolicy #PolicyDevelopment #Advocacy 

At Everyone.org, we’re lucky to have nailed our culture from the start. Finding out-of-the-box solutions for patients' needs is literally (and we're using this word correctly) what we do every day. We work as a team, learn as a team, and stay laser-focused on the reason we exist - to create fair medicine access. But not everyone across the Pharma industry is this lucky. Legacy mindsets and environments where experimentation is discouraged have no place in the future of healthcare. Thankfully, we're not the only ones who think so. This Thursday, we're joining a discussion panel at Pharmageddon 2024, focusing on Winning the Culture Wars. Join us and think along towards a future where egos aren't the stakeholders, patients are. https://lnkd.in/dQC53CkF #medicineaccess  #medicallife  #medicaleducation  #pharma  #equality #pharmageddon2024 #amsterdamevents #nl

📢Just released: IQVIA Institute’s Global Trends in R&D 2024 Report. This year’s annual report shows that industry and investors continue to see tremendous value in the vast array of ongoing research programs around the world. The report includes coverage of: 🧪Trends in new drug launches and the overall number of initiated clinical trials 🧪State of R&D funding and the activity of companies of different types 🧪New drug approvals 🧪Enablers of R&D productivity Download the full report here: https://bit.ly/42VFOEz Global Trends in R&D 2024: Activity, productivity, and enablers - IQVIA #RandDTrends #LifeSciences #Healthcare #GlobalHealth What are your thoughts Eliza Silvester, John DeMarrais, Greg Plante, Bill Jensen, Valerie Eng, Gopa Radhakrishnan, MPH?

❓ Does involving patients in drug development really make a difference? 🔍 Involving patients isn’t just a trend—it’s a game-changer. Patient insights help shape clinical trials, making them more relevant and ensuring therapies meet real-world needs. At 3D-PharmXchange, we’re committed to working closely with patient advocacy groups and innovators to co-create treatments that genuinely impact patient lives. 💡 Curious about how patient advocacy is driving progress, especially in rare disease research? Check out our latest blog to learn more: https://lnkd.in/ek6KbMCq #DrugDevelopment #Pharma #ClinicalTrials #PatientAdvocacy #OrphanDiseases #RareDiseases #PatientEngagement #HealthInnovation #LifeSciences #PrecisionMedicine #TherapeuticDevelopment #ClinicalResearch #PatientExperience #HealthCareInnovation #MedicalResearch #DrugDiscovery #PatientVoice Pivot Park Leiden Bio Science Park Amsterdam Science Park - Science & Business organisation Health & Innovation District Amsterdam (Hid) Amsterdam UMC Rotterdam Square Universitair Medisch Centrum Utrecht UMCG Maastricht UMC+ Radboudumc

We are thrilled to unveil our new promotional material that signifies a bold step forward in our commitment to innovation and excellence in the healthcare industry. This new design is more than just an update – it is a reflection of our core values and our mission to improve lives through groundbreaking research and personalized medicine. The new artwork features a vibrant DNA strand, symbolizing our dedication to advancing genomic medicine and personalized healthcare solutions. At Verma Drugs, we believe that true innovation stems from understanding and harnessing the power of genetics to create tailored treatments that meet the unique needs of each patient. Our focus on genomic medicine and personalized treatment plans ensures that we are not just keeping up with advancements but leading the way in developing cutting-edge therapies. This patient-centric approach drives everything we do, aiming to improve patient outcomes and enhance quality of life. Our commitment to staying at the forefront of global trends in healthcare means actively participating in partnerships and collaborations that drive progress in the sector. We believe in the power of teamwork and are dedicated to working alongside other industry leaders to bring about significant improvements in patient care. Our new promotional material serves as a reminder of this commitment and our continuous efforts to place patients at the centre of our innovations. We invite all our employees, partners, and industry peers to embrace this new era with us. Together, we can achieve remarkable milestones in the world of healthcare, one discovery at a time. #Innovation #Healthcare #Pharmaceuticals #GenomicMedicine #PersonalizedHealthcare #VermaDrugs #ResearchAndDevelopment #PatientCare #HealthcareInnovation

#SAFETY RELIABILITY R&D RISK RETURN #Biomedical advances are transforming healthcare globally. The multi-stakeholder #ecosystem that enables this progress has been buffeted by the global COVID-19 pandemic and is resetting and refocusing on future opportunities to advance the understanding of human #biology and disease, discover and develop new #therapeutics, and provide evidence of the clinical value of these #innovations — for individual patients, populations, and #health systems. By all of the traditional metrics, including funding levels, numbers of trial starts, drug launches, R&D success rates, and many others, it is clear that industry and investors continue to see tremendous value in the vast array of ongoing #research programs around the world.